Altimmune Stock Price, News & Analysis

Altimmune (NASDAQ:ALT) announced positive topline results from its IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The trial, involving 212 participants, demonstrated significant efficacy with up to 59.1% achieving MASH resolution without worsening of fibrosis at 24 weeks. The study showed weight loss of up to 6.2% with no plateauing and liver fat reductions of up to 62.8%.

The drug exhibited exceptional tolerability with less than 1% treatment discontinuations due to adverse events in pemvidutide-treated participants. The 1.2mg and 1.8mg doses demonstrated statistically significant improvements across multiple endpoints compared to placebo, including non-invasive tests of fibrosis. A supplemental AI-based analysis showed 30.6% of participants receiving pemvidutide 1.8mg achieved a 60% or greater reduction in fibrosis.

Altimmune (NASDAQ:ALT) has announced it will host an investor webcast on June 26, 2025, at 8:30 AM ET to present topline 24-week results from its IMPACT Phase 2b trial of pemvidutide in treating metabolic dysfunction-associated steatohepatitis (MASH). The conference call will feature remarks from Altimmune management and Dr. Mazen Noureddin, Professor of Medicine at Houston Methodist Hospital and Co-Chairman of the Board for Summit Clinical Research and Pinnacle Clinical Research.

The webcast will be available for replay on the company's Investor Relations website following the presentation. Participants can access the call by registering online to receive dial-in information.

Altimmune (NASDAQ: ALT) announced four presentations on pemvidutide, their investigational GLP-1/glucagon dual receptor agonist, at the upcoming American Diabetes Association's 85th Scientific Sessions in Chicago. The presentations include one oral presentation focusing on pemvidutide's effects on cardioinflammatory lipids in subjects with obesity, and three poster presentations covering cardiovascular safety, central adiposity measurements, and cholesterol transport studies. Pemvidutide is being developed for multiple indications including MASH, obesity, alcohol use disorder, and alcohol-associated liver disease. The presentations will take place between June 20-23, 2025, featuring research from Altimmune's senior directors Dr. John J. Suschak and Dr. Shaheen Tomah.

Altimmune (NASDAQ: ALT) has initiated the RECLAIM Phase 2 trial for pemvidutide in Alcohol Use Disorder (AUD). The trial will evaluate the drug's efficacy and safety across approximately 15 U.S. sites, enrolling about 100 subjects in a 1:1 randomization to receive either 2.4 mg pemvidutide or placebo weekly for 24 weeks.

The trial's primary endpoint focuses on changes in alcohol consumption, measured by heavy drinking days per week at Week 24. Pemvidutide, a novel GLP-1/glucagon dual receptor agonist, is also being studied for MASH, obesity, and alcohol liver disease (ALD). The company expects topline data from the IMPACT Phase 2b trial in MASH in Q2 2025 and plans to initiate a Phase 2 trial in ALD in Q3 2025.

The study addresses a significant market opportunity, with over 28 million individuals in the U.S. affected by AUD, where less than 10% receive treatment and 2% or less use approved medications.

Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, with a fireside chat at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, with a fireside chat at 9:55 AM ET. Both events will take place in New York, and webcasts will be available on Altimmune's website. The company will also be available for one-on-one meetings during these conferences.

Altimmune (ALT) has secured a credit facility of up to $100 million from Hercules Capital (HTGC), with an initial $15 million tranche funded at closing. The company, which had $150 million in cash as of March 31, 2025, will use the funds to support the development of pemvidutide, its GLP-1/glucagon dual receptor agonist. The remaining tranches include $25 million available in 2025 and $60 million in 2026, subject to clinical and financial milestones.

Pemvidutide is currently in a Phase 2b IMPACT trial for MASH with top-line data expected in Q2 2025. The company also plans to initiate Phase 2 trials for Alcohol Use Disorder and Alcohol Liver Disease in Q2 and Q3 2025. The loan features interest-only payments for 24 months (extendable to 42 months) and matures in 48 months.

Altimmune (NASDAQ: ALT) reported Q1 2025 financial results and provided key business updates. The company is approaching top-line data from its IMPACT Phase 2b trial of pemvidutide in MASH expected in Q2 2025, with 212 participants enrolled. Altimmune secured a $100 million credit facility with Hercules Capital, with $15 million funded initially. The company reported cash and equivalents of $150 million as of March 31, 2025. Q1 financial results showed R&D expenses of $15.8 million (down from $21.5 million in Q1 2024) and a net loss of $19.6 million ($0.26 per share). The company also announced plans to initiate Phase 2 trials for pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) in Q2 and Q3 2025, respectively, expanding their therapeutic pipeline.

Altimmune (Nasdaq: ALT) presented new analyses at the EASL International Liver Congress™ demonstrating the effectiveness of the MASH Resolution Index (MASHResInd) in predicting MASH resolution for patients treated with pemvidutide. The analysis showed impressive response rates, with 69.2%, 92.3%, and 90.9% of subjects receiving 1.2mg, 1.8mg, and 2.4mg of pemvidutide respectively achieving MASHResInd responses, compared to just 22.2% in the placebo group. The MASHResInd algorithm, developed by Dr. Rohit Loomba, combines multiple non-invasive tests to predict MASH resolution on biopsy. These results suggest a high probability of achieving MASH resolution in Altimmune's ongoing IMPACT Phase 2b Trial, with the company expecting to report results this quarter.

Altimmune (NASDAQ: ALT), a late clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am E.T. on the same day, during which management will discuss the financial performance and provide a business update.

Investors can access the webcast through Altimmune's Investor Relations website, and participants wishing to join the call can register to receive dial-in information. A replay of the call will be available on the company's website for up to three months following the event.